Across the recent three months, 4 analysts have shared their insights on Generation Bio (NASDAQ:GBIO), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...

Wedbush analyst David Nierengarten on Wednesday downgraded Generation Bio (GBIO) to ‘Neutral’ from ‘Outperform’ with a $7 price target after the company announced a strategic restructuring. Shares of ...

XOMA Royalty (XOMA) has entered into an agreement to acquire Generation Bio (GBIO) for a cash price of $4.2913 per share. Generation Bio stockholders also will receive one non-transferable contingent ...

Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generation Bio, which once ...

Generation Bio is a biotechnology company aiming to treat autoimmune disorders by delivering gene-silencing molecules to T cells, a specific type of immune cell. Its platform centers on a proprietary ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (GBIO) (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune ...

CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune ...

Generation Bio Co. came out with a quarterly loss of $3.12 per share versus the Zacks Consensus Estimate of a loss of $2.8. This compares to a loss of $3.1 per share a year ago. These figures are ...

Xoma Royalty is acquiring the pharmaceutical company Generation Bio. Xoma, a biotechnology-royalty aggregator, said Monday that it would pay roughly $4.29 a share for the company. Generation Bio ...